JP2003515533A5 - - Google Patents

Download PDF

Info

Publication number
JP2003515533A5
JP2003515533A5 JP2001537359A JP2001537359A JP2003515533A5 JP 2003515533 A5 JP2003515533 A5 JP 2003515533A5 JP 2001537359 A JP2001537359 A JP 2001537359A JP 2001537359 A JP2001537359 A JP 2001537359A JP 2003515533 A5 JP2003515533 A5 JP 2003515533A5
Authority
JP
Japan
Prior art keywords
hemoglobin
mammal
mutations
kilodaltons
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001537359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515533A (ja
JP5099951B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/030857 external-priority patent/WO2001034648A1/en
Publication of JP2003515533A publication Critical patent/JP2003515533A/ja
Publication of JP2003515533A5 publication Critical patent/JP2003515533A5/ja
Application granted granted Critical
Publication of JP5099951B2 publication Critical patent/JP5099951B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001537359A 1999-11-12 2000-11-10 副作用が減少されたヘモグロビン組成物 Expired - Fee Related JP5099951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16528999P 1999-11-12 1999-11-12
US60/165,289 1999-11-12
PCT/US2000/030857 WO2001034648A1 (en) 1999-11-12 2000-11-10 Reduced side-effect hemoglobin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011030290A Division JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Publications (3)

Publication Number Publication Date
JP2003515533A JP2003515533A (ja) 2003-05-07
JP2003515533A5 true JP2003515533A5 (enExample) 2007-12-27
JP5099951B2 JP5099951B2 (ja) 2012-12-19

Family

ID=22598286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001537359A Expired - Fee Related JP5099951B2 (ja) 1999-11-12 2000-11-10 副作用が減少されたヘモグロビン組成物
JP2011030290A Pending JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011030290A Pending JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Country Status (8)

Country Link
US (2) US6670323B1 (enExample)
EP (2) EP1233986A4 (enExample)
JP (2) JP5099951B2 (enExample)
AU (1) AU784195B2 (enExample)
CA (1) CA2391226A1 (enExample)
NO (1) NO20022229L (enExample)
WO (1) WO2001034648A1 (enExample)
ZA (1) ZA200203817B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233986A4 (en) * 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US7092752B2 (en) * 2002-07-27 2006-08-15 Sheng-Xing Ma Skin acupoint/meridian nitric oxide collection kit and method thereof
US9138707B2 (en) 2002-12-10 2015-09-22 Sy Kimball Portable, nitric oxide generator
DE60304989T2 (de) * 2003-02-18 2007-03-29 Clinique La Prairie Research S.A. Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
DE602005023191D1 (de) * 2004-08-31 2010-10-07 Sangart Inc Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen
US7976866B2 (en) * 2004-12-06 2011-07-12 Opremcak E Mitchel Bandage and method for vital bleaching of skin
US7935074B2 (en) 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
WO2006135740A1 (en) * 2005-06-10 2006-12-21 Albert Einstein College Of Medicine Of Yeshiva University Pegylated hemoglobin and albumin and uses thereof
WO2007058678A2 (en) * 2005-06-10 2007-05-24 Albert Einstein College Of Medicine Of Yeshiva University Uses of pegylated albumin
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
US8434475B2 (en) 2008-01-31 2013-05-07 Genosys, Inc. Nitric oxide reactor and distributor apparatus and method
US9649467B2 (en) 2008-01-31 2017-05-16 Syk Technologies, Llc Nitric oxide reactor and distributor apparatus and method
US8720436B2 (en) * 2008-01-31 2014-05-13 Genosys, Inc. Nitric oxide gel apparatus and method
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US8501090B2 (en) * 2008-03-24 2013-08-06 Christian S. Minton Anti-microbial gas apparatus and method
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
WO2011008858A1 (en) 2009-07-15 2011-01-20 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
US8685467B2 (en) 2010-08-03 2014-04-01 J. W. Randolph Miller Nitric oxide generation, dilution, and topical application apparatus and method
US8609815B2 (en) * 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
US9694125B2 (en) 2010-12-20 2017-07-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
CN103648540B (zh) 2011-04-21 2016-06-01 弗雷塞尼斯医疗保健控股公司 医疗流体泵送系统及相关装置和方法
PL2550973T3 (pl) 2011-07-23 2014-03-31 Sastomed Gmbh Sprej do ran
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
IN2014MN02089A (enExample) 2012-03-20 2015-09-11 Einstein Coll Med
US20130261412A1 (en) * 2012-03-28 2013-10-03 II Robert Lawrence Reed System and method for managing fluid levels in patients based upon creatinine clearance
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
JP2014062050A (ja) * 2012-09-19 2014-04-10 Fujifilm Corp 多価官能マレイミド系重合性化合物、これを含む硬化組成物およびインク組成物
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
AR102048A1 (es) 2014-08-12 2017-02-01 Baxalta Inc Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING
GB201721503D0 (en) * 2017-12-20 2018-01-31 Univ Essex Modified globin proteins
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
JP7593609B2 (ja) * 2020-02-28 2024-12-03 学校法人 中央大学 ヘモグロビン微粒子及び人工酸素運搬体
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy
US11857605B2 (en) 2021-03-01 2024-01-02 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
AU2022345865A1 (en) * 2021-09-17 2024-03-14 Yale University Methods, systems and compositions for restoration and preservation of intact organs in a mammal
CN115317595A (zh) * 2021-09-27 2022-11-11 中国人民解放军军事科学院军事医学研究院 一种聚乙二醇化牛血红蛋白氧载体及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3525272A (en) 1967-10-20 1970-08-25 Westinghouse Air Brake Co Multiposition control handle having detent means
DE2449885C3 (de) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4061736A (en) 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4473496A (en) 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
DE3144705C2 (de) 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4868119A (en) 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
DE3636590A1 (de) 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
EP0561245A1 (en) * 1987-05-16 1993-09-22 Somatogenetics International, Inc. Blood substitutes comprising recombinant hemoglobin
JP2562840B2 (ja) 1988-08-01 1996-12-11 富士通株式会社 電界効果トランジスタ
IL87707A (en) 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5844090A (en) 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
US5173426A (en) 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
HUT62011A (en) 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
US5478806A (en) 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
EP0459788A3 (en) 1990-06-01 1992-01-22 Common Services Agency Modified proteins and methods of producing same
WO1992020369A1 (en) 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5334706A (en) 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
IL106401A (en) 1992-08-07 1997-02-18 Donnelley & Sons Co Method and system for converting bitmap data into page definition language commands
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5665869A (en) 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US5559907A (en) 1994-02-17 1996-09-24 Lucent Technologies Inc. Method of controlling polarization properties of a photo-induced device in an optical waveguide and method of investigating structure of an optical waveguide
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
WO1998017289A1 (en) 1996-10-21 1998-04-30 Baxter International Inc. Therapeutic use of hemoglobin to treat head injury
WO1998050430A2 (en) * 1997-05-02 1998-11-12 Somatogen, Inc. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
EP1233986A4 (en) * 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
EP2340681B1 (en) 2008-09-25 2014-11-12 Nokia Corporation Synchronization for device-to-device communication
WO2010099216A2 (en) 2009-02-25 2010-09-02 California Institute Of Technology Methods for fabrication of high aspect ratio micropillars and nanopillars
JP5963422B2 (ja) 2010-12-17 2016-08-03 キヤノン株式会社 撮像装置、表示装置、コンピュータプログラムおよび立体像表示システム

Similar Documents

Publication Publication Date Title
JP5099951B2 (ja) 副作用が減少されたヘモグロビン組成物
JP2022530615A5 (enExample)
JP4173913B2 (ja) Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
JP6755175B2 (ja) インスリン投薬レジメン
ES2260916T3 (es) Preparacion en polvo para administracion a traves de la mucosa que contiene una medicina polimerica.
ES2217327T3 (es) Proteina ob para aumentar la masa de tejido magro.
US9034815B2 (en) Polypeptide for treating or preventing adhesions
EP2640411B1 (en) Interleukin-2 by subligual administration for use in the treatment of inflammation
JP2005526126A (ja) インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
TW201109034A (en) Hemoglobin compositions
D’Souza et al. Nasal insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies
JPH05502234A (ja) ペプチド製剤
PT639079E (pt) Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
PT726778E (pt) Sistema de administracao oral de proteinas g-csf modificadas quimicamente
JP2025163025A5 (enExample)
JP2003500456A (ja) 角質細胞増殖因子−２製剤
JP2010526093A (ja) 血管新生を増大させるための組成物および方法
JP4726797B2 (ja) 消耗症に罹患している患者の治療における成長ホルモン放出因子類似体の使用
JP2010163457A (ja) 脈管形成に有効な単位用量のｆｇｆ−２および使用方法
JP2024524273A (ja) マズチドの使用
JP2002534479A5 (enExample)
JP2001501619A (ja) ｍｐｌリガンドを含有する医薬組成物
TWI921426B (zh) 治療糖尿病之方法
NZ532719A (en) Thymosin alpha 1 peptide polymer conjugates for increasing half life of the peptide in serum
JP2002539827A5 (enExample)